What is the purpose of this trial?
This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
National Cancer Institute
Dates: 06/06/2017 - 05/31/2026
Last Updated: 09/10/2017
Study HIC#: 2000020555